Skip to contentM
Mangoceuticals, Inc.
M
MGRXMangoceuticals, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$94.36K$94.36Kderived−10.3% vs Q4 2024 Net Income-$2.77M-$2.77MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$47,475−40.7% Operating Incomederived-$644,554N/M Operating Cash Flowderived-$1,077,761N/M Margins · derivedGross margin50.3%−25.8 pt vs Q4 2024
Operating margin-683.1%+910.9 pt vs Q4 2024
Net margin-2935.1%−1083.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Apr 1, 2026 · 91 d after period end